Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;66(3):262-269.
doi: 10.1002/mus.27662. Epub 2022 Jul 8.

Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy

Joel Iff  1 , Charles Gerrits  1 , Yi Zhong  2 , Edward Tuttle  2 , Erica Birk  2 , Yeya Zheng  2 , Xander Paul  2 , Erik K Henricson  3 , Craig M McDonald  3 ; CINRG-DNHS Investigators
Affiliations

Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy

Joel Iff et al. Muscle Nerve. 2022 Sep.

Abstract

Introduction/aims: Pulmonary decline is a major issue in patients with Duchenne muscular dystrophy (DMD). Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations. Previous analyses have shown that eteplirsen is associated with a statistically significant attenuation of pulmonary decline. In this study we evaluate the effect of eteplirsen treatment from newly available data sources on pulmonary function over time in patients with DMD.

Methods: We used a post hoc pooled analysis to compare the percentage of predicted forced vital capacity (FVC%p) and projected time with pulmonary function milestones in patients with DMD and exon 51 skip-amenable mutations receiving eteplirsen (Studies 204 and 301) or standard of care (SoC; Cooperative International Neuromuscular Research Group Duchenne Natural History Study). A mixed model for repeated-measures framework was applied to evaluate the impact of eteplirsen.

Results: An average annual rate of FVC%p decline for eteplirsen-treated patients was estimated to be 3.47%, a statistically significant attenuation from the 5.95% rate of decline estimated in SoC patients (P = .0001). Using linear extrapolations of the model-estimated decline in FVC%p, the attenuation in FVC%p decline for eteplirsen-treated patients corresponded to a delay of 5.72 years in time to needing continuous ventilation, 3.31 years in time to needing nighttime ventilation, and 2.11 years in time to needing a cough assist device compared with SoC patients.

Discussion: The attenuation of FVC%p decline suggests that eteplirsen-treated patients had statistically significant and clinically meaningful attenuations in pulmonary decline compared with SoC patients.

Keywords: Duchenne muscular dystrophy; clinical trial; eteplirsen; muscular dystrophy; pulmonary function.

PubMed Disclaimer

References

REFERENCES

    1. Tsuda T. Clinical manifestations and overall management strategies for Duchenne muscular dystrophy. Methods Mol Biol. 2018;1687:19-28.
    1. Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR. Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis. 2018;5:47-58.
    1. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170:456-465.
    1. Benditt JO, Boitano L. Respiratory support of individuals with Duchenne muscular dystrophy: toward a standard of care. Phys Med Rehabil Clin N Am. 2005;16:1125-1139. xii.
    1. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347-361.

Publication types

LinkOut - more resources